Bio-Path Holdings, Inc. (NASDAQ:BPTH) Short Interest Update

Bio-Path Holdings, Inc. (NASDAQ:BPTH) was the recipient of a significant increase in short interest in the month of October. As of October 15th, there was short interest totalling 388,600 shares, an increase of 3,947.9% from the September 30th total of 9,600 shares. Approximately 10.5% of the company’s shares are short sold. Based on an average trading volume of 1,390,000 shares, the short-interest ratio is presently 0.3 days.

Institutional Trading of Bio-Path

An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC purchased a new stake in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned approximately 4.66% of Bio-Path at the end of the most recent quarter. Hedge funds and other institutional investors own 5.74% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on BPTH. StockNews.com initiated coverage on Bio-Path in a report on Wednesday. They issued a “sell” rating on the stock. Roth Mkm restated a “buy” rating and issued a $20.00 price target on shares of Bio-Path in a report on Monday, July 8th.

Bio-Path Stock Up 2.8 %

Shares of Bio-Path stock opened at $1.10 on Friday. Bio-Path has a twelve month low of $0.85 and a twelve month high of $14.42. The company has a fifty day moving average price of $1.05 and a 200 day moving average price of $1.81.

Bio-Path (NASDAQ:BPTH) last issued its earnings results on Thursday, August 15th. The company reported ($1.16) earnings per share for the quarter, topping the consensus estimate of ($1.54) by $0.38. During the same period in the previous year, the company posted ($10.60) earnings per share. Equities research analysts expect that Bio-Path will post -6.2 earnings per share for the current fiscal year.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.